Vitiligo
Conditions
Interventions
Case series:transplantation of hair follicle melanocyte suspension
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Stable vitiligo patients, indicated by at least 2 of the following 4 criterias: (1) the VIDA score is 0 point; (2) clinical features: porcelain white spots with sharpened edges or pigmentation; (3) no evidence of Koebner Phenomenon for not less than a year; (4) evidenced by the wood lamp: the lesion is white in color, with sharpened edges; the lesion area is not more than that measured by visual inspection; 2. Aged between 18 and 65 years; 3. The lesion is less than 10% of body surface area, non-exposed; 4. Other treatments have been ineffective for the last year, including glucocorticoids, phototherapy, laser therapy, topical vitamin D3 derivatives, topical calcineurin inhibitors; 5. Subjects volunteer and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with keloidal tendency; 2. Patients with sebrrheic alopecia; 3. Patients with autoimmune diseases such as lupus erythematosus, scleroderma, dermatomyositis; 4. Pregnancy or planning pregnancy during the study period; 5. Other acute or chronic skin diseases present close to the lesion or the scalp donor area; 6. Patients with infectious diseases such as HBV, HCV, AIDS, syphilis, tuberculosis; 7. Patients with serious primary heart, liver, lung, kidney, blood disease, diabetes, thyroid disease or patients with a history of serious diseases affecting their survival, such as cancer or patients undergoing radiotherapy, chemotherapy, or immunotherapy; 8. Patients with long-term using of anticoagulant drugs; 9. Patients who are not fully informed consent due to mental and behavioral disorders; 10. Patients who received topical drugs for treating vitiligo in the last two weeks; 11. Patients who received systematic drugs or phototherapy for treating vitiligo in the last four weeks; 12. Patients who are allergic to dialysis membrane and lidocaine; 13. Patients having a uncertain or certain history of alcohol or drug abuse; 14. Patients with other lesions that complicate the enrollment or reduce the likelihood of enrollment, as judged by the researchers. For instance, frequent changes of work locations may easily cause loss of follow-up; 15. Patients who have participated in or are participating in other clinical trials within 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vesta; | — |
Secondary
| Measure | Time frame |
|---|---|
| improvement rate of melanin index;improvement rate of skin CT gray value; | — |
Countries
China
Contacts
Public ContactXiang Leihong
Huashan Hospital, Fudan University
Outcome results
None listed